Disease Intelligence Center · Fifth Estate / I

Gut Dysbiosis & SIBO

Dysbiosis means an unhealthy change in gut microbes. It is a research concept, and there is no validated lab test for it. Stool microbiome panels are not recommended for diagnosis. The parts that can be measured are small-intestinal bacterial overgrowth (SIBO) and gut inflammation. SIBO is shown by a lactulose or glucose breath test with a hydrogen rise of 20 ppm or more within 90 minutes, or methane of 10 ppm or more (North American Consensus 2017). Gut inflammation is shown by fecal calprotectin above about 50 µg/g, which calls for workup to exclude inflammatory bowel disease.

Domain weighting

Organizational emphasis

T Toxins0.6

O Oxidative Stress0.5

B Hormonal Balance0.5

I Inflammation & Infection1

N Nutrition0.9

iWeightings describe where this framework directs attention for this condition. They are not a measure of how much any factor caused an individual case.

Root-cause chain

Each link carries its own evidence grade

Antibiotics, low-fiber diet→Loss of microbial diversityNB
Fiber feeding trials raise short-chain-fatty-acid producers; antibiotics reduce diversity for months.
Relationship: Randomized evidence
Reduced gut motility (diabetes, opioids, hypothyroidism)→SIBOBB
Impaired migrating motor complex lets bacteria accumulate in the small bowel.
Relationship: Observational association
Dysbiosis→Systemic low-grade inflammationIC
Endotoxin translocation raises inflammatory signalling; human causation remains unproven.
Relationship: Mechanistic plausibility
SIBO→Bloating, B12 and iron malabsorptionNB
Bacterial consumption of B12 and mucosal injury.
Relationship: Observational association

iDetection of an exposure does not establish that it caused a disease. This platform separates exposure, association, plausible mechanism, clinical evidence and demonstrated causation.

Fifth Estate considerations

Microbial ecology

Bacteria are the subject here. Treat SIBO only when a breath test is positive. Probiotics and FMT are proven only for specific indications, such as recurrent C. difficile.

Go deeper

TOBIN Intelligence Library

Gut Dysbiosis & SIBO on TOBINintel.org →

The full evidence review for Gut Dysbiosis & SIBO: each mechanism by domain, what is established versus uncertain, related pandemics, relevant labs and how they move your scores.

Open the Gut Dysbiosis & SIBO evidence review

Protocol Fusion Engine

Six lanes · evidence grade and regulatory status on every entry

Conventional

Rifaximin 550 mg three times daily for 14 days for breath-test-positive SIBOBOff-label

ACG 2020 SIBO guideline; also FDA-approved for IBS-D (TARGET trials).

Caution: Recurrence is common; treat the underlying motility cause.

Functional

Low-FODMAP diet trial (2–6 weeks) then reintroductionBLifestyle

Reduces bloating in IBS RCTs; reintroduction prevents long-term restriction.

Caution: Use a dietitian; can reduce microbial diversity if kept long term.

Integrative

Increase dietary fiber diversity graduallyBLifestyle

Raises short-chain-fatty-acid producers in feeding trials.

Caution: Can worsen bloating at first, especially in SIBO.

Orthomolecular

Strain-specific probiotics only for evidence-backed indicationsCSupplement

AGA 2020 recommends probiotics only in clinical-trial settings for most GI conditions.

Caution: Avoid in severely immunocompromised patients and central lines.

Traditional

Herbal antimicrobials (e.g. berberine-containing blends) for SIBODSupplement

One retrospective study (Chedid 2014) suggested similar response to rifaximin.

Caution: Berberine interacts with many drugs (CYP3A4, metformin); not for pregnancy.

Energy / Physical

Energy medicine on Tayapulse →

No energy modality treats dysbiosisEInvestigational

Listed for completeness only.

Caution: Must not be presented as a treatment.

iLanes are presented side by side so the difference in evidence strength is visible. Nothing here is a prescription, and interactions must be reviewed with your clinician and pharmacist.

iEnergy and physical modalities in this lane are explored further with Tayapulse. Evidence grade and regulatory status still apply: these are adjuncts used only where indicated, never cures or replacements for guideline care.

Diagnostics to consider

· Lactulose or glucose hydrogen/methane breath test
· Fecal calprotectin (exclude IBD)
· Celiac serology (tTG-IgA)
· B12, ferritin, vitamin D (malabsorption)
· Medication review: PPIs, opioids, antibiotics

Monitoring

· Symptom diary (bloating, stool form)
· Repeat breath test only if symptoms recur
· B12 and ferritin after treatment
· TOBIN score change over time

Prevention emphasis

· 25–35 g/day dietary fiber from varied plants
· Avoid unnecessary antibiotics and long-term PPIs
· Fermented foods as tolerated

Obesity & Metabolic Dysfunction Type 2 Diabetes Asthma & Allergic Airway Disease PCOS & Hormonal Dysregulation Depressive & Anxiety Disorders IBS & Gut Barrier Dysfunction Hypothyroidism & Hashimoto's Thyroiditis Fatty Liver Disease (MASLD)Iron Deficiency & Anemia Insulin Resistance (Prediabetes Pattern)HPA-Axis Dysregulation (often called "adrenal fatigue")